Product Reports Resources Pricing Login Book a demo

Terremoto Biosciences

Biotech & Life Sciences · San Francisco, United States · Founded 2021

Terremoto Biosciences is a pioneering startup operating in the pharmaceutical industry, specifically in the drug development sector. The company is revolutionizing the field with its innovative covalent chemistry approach. In simpler terms, they are developing new drugs using a unique method that involves creating strong bonds between molecules, which can lead to more effective medicines. Historically, covalent medicines have targeted a specific amino acid called cysteine. Terremoto Biosciences, however, is leveraging a different amino acid, lysine, to expand the range of potential drug targets. This could not only broaden the scope of diseases that can be treated but also enhance the efficacy of existing medicines. The company's business model revolves around the research, development, and commercialization of these novel covalent medicines. Their revenue is likely to be generated from the sales of these drugs once they have been successfully developed and approved for use. Terremoto Biosciences serves a broad range of clients, primarily within the healthcare sector. These could include hospitals, clinics, and other healthcare providers, as well as patients in need of their innovative treatments. The company prides itself on its inclusive culture of excellence, seeking a diverse team of chemists, biologists, and industry-leading drug developers. Their commitment to innovation and excellence is reflected in their tenacious work ethic, inventive scientific approach, and unwavering drive to deliver superior therapeutics to patients. Keywords: Drug Development, Covalent Medicines, Lysine-Based Covalency, Pharmaceutical Industry, Innovative Therapeutics, Healthcare Sector, Inclusive Culture, Chemists, Biologists, Drug Developers.

Investors

10 investors on Terremoto Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
OrbiMed
Third Rock Ventures
Novo Holdings
EcoR1 Capital
Cormorant Capital
Series B+ 5 investors entered at this stage
Cormorant Asset Management
RA Capital Management
BeOne Medicines
Deep Track Capital
Osage University Partners

Global footprint

Where Terremoto Biosciences has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Talent graph

The shape of Terremoto Biosciences's talent

Dealroom maps Terremoto Biosciences's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

6 team members profilednamed & role-tagged by Dealroom
52 employeestotal headcount
1 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Terremoto Biosciences's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Terremoto Biosciences

An AI-synthesized read of the highest-engagement posts about Terremoto Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Terremoto Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.